标题
Pharmacology and Clinical Development of Factor XI Inhibitors
作者
关键词
-
出版物
CIRCULATION
Volume 147, Issue 11, Pages 897-913
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2023-03-14
DOI
10.1161/circulationaha.122.062353
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study
- (2022) Dagmar Kubitza et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
- (2022) Connie W. Tsao et al. CIRCULATION
- First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects
- (2022) Rui Chen et al. Frontiers in Pharmacology
- First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
- (2022) Bettina Nowotny et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
- (2022) Stefan Heitmeier et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
- (2022) Jonathan P Piccini et al. LANCET
- Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence
- (2022) Stephan Nopp et al. Frontiers in Cardiovascular Medicine
- Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor
- (2022) Vidya Perera et al. Cardiology and Therapy
- A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction
- (2022) Sunil V. Rao et al. CIRCULATION
- Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention
- (2022) Mukul Sharma et al. Journal of Stroke & Cerebrovascular Diseases
- Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial
- (2022) Ashkan Shoamanesh et al. LANCET
- A coagulation factor moonlights in the heart
- (2022) Dan Tong et al. SCIENCE
- Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure
- (2022) Yang Cao et al. SCIENCE
- A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study
- (2022) Holger Reinecke et al. CIRCULATION
- Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial
- (2022) Sean D. Pokorney et al. CIRCULATION
- ONO‐7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human study
- (2021) Dominic Beale et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low‐density lipoprotein receptor‐deficient mice
- (2021) Anh T.P. Ngo et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Atrial Fibrillation
- (2021) Gregory F. Michaud et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contact Activation Inhibitor, AB023, in Heparin-Free Hemodialysis: Results of a Randomized Phase 2 Clinical Trial
- (2021) Christina U. Lorentz et al. BLOOD
- Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC
- (2021) Gerhard Hindricks et al. EUROPEAN HEART JOURNAL
- Factor XI Inhibition to Uncouple Thrombosis From Hemostasis
- (2021) Charles Hsu et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
- (2021) Dirk Thomas et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Abelacimab for Prevention of Venous Thromboembolism
- (2021) Peter Verhamme et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
- (2021) Dawn O. Kleindorfer et al. STROKE
- Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events
- (2021) Davide Capodanno et al. European Heart Journal-Cardiovascular Pharmacotherapy
- PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients
- (2021) Stefan Willmann et al. CPT-Pharmacometrics & Systems Pharmacology
- First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor
- (2021) Vidya Perera et al. CTS-Clinical and Translational Science
- Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa
- (2021) B. Alexander Yi et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
- (2021) Pancras C. Wong et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Milvexian for the Prevention of Venous Thromboembolism
- (2021) Jeffrey I. Weitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD
- (2021) Michael Walsh et al. Kidney International Reports
- Preventing covert brain infarct-related cognitive impairment and dementia
- (2020) Romella Durrani et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty
- (2020) Jeffrey I. Weitz et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Role of Factor XIa and Plasma Kallikrein in Arterial and Venous Thrombosis
- (2020) Mayken Visser et al. THROMBOSIS AND HAEMOSTASIS
- Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery
- (2020) Qingxin Li et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges
- (2020) Ashley Chen et al. Journal of the American Heart Association
- Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands
- (2019) Maxwell D. Cummings et al. JOURNAL OF MEDICINAL CHEMISTRY
- 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
- (2019) Craig T. January et al. CIRCULATION
- MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans
- (2019) Alexander W. Koch et al. BLOOD
- Therapeutic Antisense Oligonucleotides Are Coming of Age
- (2019) C. Frank Bennett Annual Review of Medicine
- Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial
- (2019) Christina U. Lorentz et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc3-Conjugated Antisense Oligonucleotides
- (2019) Yanfeng Wang et al. Expert Opinion on Drug Metabolism & Toxicology
- Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass
- (2019) Valérie Pireaux et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI
- (2019) Martina Schaefer et al. JOURNAL OF MOLECULAR BIOLOGY
- First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects
- (2018) Vidya Perera et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction
- (2018) Tatjana S. Potpara et al. Nature Reviews Nephrology
- ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy
- (2018) Davide Capodanno et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mortality and causes of death in patients with atrial fibrillation: A nationwide population-based study
- (2018) Euijae Lee et al. PLoS One
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
- (2017) John W. Eikelboom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces
- (2017) Benjamin Tillman et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- Generation and characterization of aptamers targeting factor XIa
- (2017) R.S. Woodruff et al. THROMBOSIS RESEARCH
- The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
- (2017) Stanley T. Crooke et al. Nucleic Acid Therapeutics
- Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa
- (2017) David A. Donkor et al. Scientific Reports
- The atrial fibrillation conundrum in dialysis patients
- (2016) An S. De Vriese et al. AMERICAN HEART JOURNAL
- Factor XI as a Therapeutic TargetHighlights
- (2016) David Gailani et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events
- (2016) Meir Preis et al. BLOOD
- In Vitro Mode of Action and Anti-thrombotic Activity of Boophilin, a Multifunctional Kunitz Protease Inhibitor from the Midgut of a Tick Vector of Babesiosis, Rhipicephalus microplus
- (2016) Teresa C. Assumpção et al. PLoS Neglected Tropical Diseases
- Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor
- (2015) C. Puy et al. BLOOD
- Medical device-induced thrombosis: what causes it and how can we prevent it?
- (2015) I. H. Jaffer et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
- (2015) Harry R. Büller et al. NEW ENGLAND JOURNAL OF MEDICINE
- The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis
- (2014) C. Chai-Adisaksopha et al. BLOOD
- Factor XIII activity mediates red blood cell retention in venous thrombi
- (2014) Maria M. Aleman et al. JOURNAL OF CLINICAL INVESTIGATION
- Designing Allosteric Inhibitors of Factor XIa. Lessons from the Interactions of Sulfated Pentagalloylglucopyranosides
- (2014) Rami A. Al-Horani et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity
- (2014) W. Chen et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo
- (2013) D. Ma et al. BLOOD
- Evolution and Emergence of Therapeutic Monoclonal Antibodies
- (2013) Ian N. Foltz et al. CIRCULATION
- Sulfated Pentagalloylglucoside Is a Potent, Allosteric, and Selective Inhibitor of Factor XIa
- (2013) Rami A. Al-Horani et al. JOURNAL OF MEDICINAL CHEMISTRY
- Evidence for factor IX-independent roles for factor XIa in blood coagulation
- (2013) A. Matafonov et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys
- (2012) H. S. Younis et al. BLOOD
- Prevention of VTE in Orthopedic Surgery Patients
- (2012) Yngve Falck-Ytter et al. CHEST
- Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
- (2011) Jessica L. Mega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of an anticoagulant peptide that inhibits both fXIa and fVIIa/tissue factor from the blood-feeding nematode Ancylostoma caninum
- (2010) Deng Li et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk
- (2010) H. Zhang et al. BLOOD
- Structure and function of factor XI
- (2010) J. Emsley et al. BLOOD
- Development trends for human monoclonal antibody therapeutics
- (2010) Aaron L. Nelson et al. NATURE REVIEWS DRUG DISCOVERY
- Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis
- (2010) Ophira Salomon et al. THROMBOSIS AND HAEMOSTASIS
- Ir-CPI, a coagulation contact phase inhibitor from the tickIxodes ricinus, inhibits thrombus formation without impairing hemostasis
- (2009) Yves Decrem et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
- (2009) Lars Wallentin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduced incidence of ischemic stroke in patients with severe factor XI deficiency
- (2008) O. Salomon et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started